Metabolic syndrome (MS) has recently been shown to be a forerunner of chronic kidney disease (CKD). Microalbuminuria (MA) is associated with both MS and CKD. This study aimed to prospectively investigate the relationship among MA, MS and renal outcome in nondiabetic patients with primary hypertension. A total of 790 hypertensive patients enrolled in the MAGIC study between 1993 and 1997 (mean age 49.3 ± 10.7 years) were included in the analysis. Renal outcome was defined as the first hospitalization with a diagnosis of CKD. At baseline, 146 (19%) and 60 (7.6%) patients met MS and MA criteria, respectively. A total of 20 patients (2.5%) concomitantly showed MS and MA. After a median follow-up of 11.6 years (interquartile range 3.2 years), renal end point was reached in 15.8% of patients with MS and in 8.9% of those without it (P ¼ 0.0087). The incidence of renal events increased progressively starting from patients with neither MS nor MA, to patients with only one of these abnormalities and then to those with both. Significant interaction was observed between MS and MA. Patients with concomitant occurrence of MS and MA at baseline showed a greater than fivefold risk of renal outcome, as compared with patients with neither of these two risk factors (hazard ratio 5.46; 95% confidence interval 2. 34-12.75). This risk became even higher when data were adjusted for potential confounders. MS and MA are independent and interactive predictors of renal outcome in non-diabetic patients with primary hypertension.
Introduction
Chronic kidney disease (CKD) is associated with adverse long-term prognosis, mainly related to a greater burden of cardiovascular diseases. The prevalence of CKD is on the rise worldwide and this condition is rapidly becoming a major clinical and public health problem. 1 Early detection and treatment of risk factors associated with the presence of CKD may improve the outcome and quality of life in a considerable number of patients, and may also reduce the costs of end-stage renal disease. 2 Metabolic syndrome (MS) has been acknowledged as a forerunner of diabetes and subsequent cardiovascular events. 3 Emerging epidemiological data suggest that MS may also contribute to the development of CKD. 4 MS is a relatively common finding in Western countries and its prevalence is expected to further increase in the near future. 5 Thus, the issue of an association between MS and the development or progression of CKD might soon become one of clinical and socioeconomic relevance. Microalbuminuria (MA) is a well-known predictor of cardiovascular and renal diseases. [6] [7] [8] [9] Previously reported associations between MA and components of MS had led the World Health Organization to include the former abnormality among the defining criteria of MS. 10 However, because of the inconsistent relationship between MA and insulin resistance, 11, 12 more recent definitions of MS no longer include MA. [13] [14] [15] To date, the combined effect of MS and MA on renal outcome has not yet been investigated. Therefore, it is currently unclear whether MA adds to the predictive power of MS or whether the two abnormalities provide overlapping information on risk status. Regardless of the underlying pathophysiological mechanisms, this point could have practical implications with respect to identifying clinical variables to consider for risk assessment and possibly for treatment strategies. The aim of this study was to prospectively evaluate the relationship among MA, MS and the development of CKD in nondiabetic patients with primary hypertension.
Materials and methods

Study population
The design and main cross-sectional results of the MAGIC study (Microalbuminuria: A Genoa Investigation on Complications) have previously been described. 16 In brief, a total of 1230 patients with primary hypertension were recruited between 1993 and 1997 from among those attending several outpatient hypertension clinics in the Genoa area (for a list of participating centres see ref. 16 ).
Exclusion criteria were age o18 years, evidence of neoplastic, hepatic and/or renal disease (defined as serum creatinine 4133 mmol l À1 in males and 4124 mmol l À1 in females or overt proteinuria), chronic heart failure (New York Heart Association class III and IV), diabetes mellitus, severe obesity (body weight 4150% of ideal body weight), severe hypertension (systolic blood pressure (BP) X180 mm Hg and/or diastolic BP X110 mm Hg) and disabling diseases such as dementia or the inability to cooperate. More than 90% of the remaining patients (n ¼ 1122; 614 men and 508 women) agreed to participate in the study. Diagnosis of primary hypertension was made by the attending physician after complete medical history, physical examination and routine biochemical analyses of blood and urine had been obtained from the patients.
Hypertension was defined as an average BP X140/ 90 mm Hg on at least three different occasions, or by the presence of antihypertensive treatment. None of the patients showed evidence or history of congestive heart failure, ischaemic cardiopathy or advanced chronic obstructive pulmonary disease. Data on the patients (n ¼ 205; 106 men and 99 women) who either did not comply with washout instructions (63 patients), failed to collect urine samples properly (67 patients) or had to resume treatment because of severe hypertension during the washout period (61 patients) were excluded from analysis. Nine patients (5 men and 4 women) were excluded because of hypokalemia (serum K o3.5 mmol l À1 ) and five because of macroalbuminuria (albumin to urinary creatinine ratio (ACR) 425 mg mmol À1 in males and 435 mg mmol À1 in females in the presence of a normal routine urine examination). Participation was voluntary, and each participant provided written informed consent. All surveys were approved by the ethics committee of our institution. Data obtained from the remaining 917 patients (514 men and 403 women; all Caucasian) form the basis of the present report.
As a matter of fact, our study only includes patients for whom it was possible to define the presence or absence of MS, thus meaning an analytic cohort of 790 subjects.
None of the patients were on medication at the time of the study. They either had never been treated for hypertension (79%, n ¼ 725) or had been taken off therapy at least 4 weeks before the study (21%, n ¼ 192).
Baseline measurements
At the end of the washout period, if any, during the baseline visit with the clinical research staff, height, weight, BP values, family history and lifestyle habits were recorded. BP was measured by a trained nurse, with the patient in the sitting position after a 5-min rest, with a mercury sphygmomanometer (cuff size 12.5 Â 40 cm). The systolic and diastolic BPs were read to the nearest 2 mm Hg. Disappearance of Korotkoff sounds (phase V) was the criterion for diastolic BP. Three consecutive readings were performed, and the average was recorded.
Body weight was measured in light clothing without shoes to the nearest 0.1 kg by using a digital weight scale. Height was measured to the nearest 0.1 cm. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. Venous blood was drawn after an overnight fast for laboratory examinations, and albuminuria was evaluated by measuring the urinary ACR. The mean of three non-consecutive first morning samples was recorded. Only samples from patients with negative urine cultures were collected. The urine albumin concentration was measured using a commercially available radioimmunoassay kit (Pantec, Torino, Italy) in a core laboratory. The interand intra-assay coefficient of variation was 6.1 and 4.5%, respectively. Urinary creatinine was measured by Jaffe's kinetic method and inter-and intra-assay coefficient of variations were 2.7 and 1.6%, respectively. MA was defined as an ACR value X2.5 mg mmol À1 in men and ACR X3.5 mg mmol
À1
in women. Creatinine clearance was estimated by the Cockcroft-Gault formula using ideal body weight and normalized for body surface area. According to the National Cholesterol Education Program Adult Treatment Panel III, 13 the following five abnormalities define the presence of MS: (1) abdominal obesity; (2) fasting blood glucose level of X6.1 mmol l À1 ; (3) triglyceride level of X1.7 mmol l À1 ; (4) HDL-cholesterol level o1.04 mmol l À1 in men and o1.3 mg dl À1 in women; and (5) BP of X130/ 85 mm Hg. As data regarding waist circumference were not available, a modified ATP III definition for MS (abdominal obesity ¼ BMI X30 kg m À2 ) was used. Considering that all patients were hypertensive, subjects with two or more of the remaining four abnormalities were considered as having MS. Missing data on some risk factors made us to classify patients as not having MS in the absence of three MS risk factors, and conversely, to classify patients as having MS in the presence of two risk factors.
Clinical outcomes
Renal outcome was defined as the first hospitalization with a diagnosis of CKD. All clinical end points, including hospital admission and mortality, were censored on 17 June 2006 using the following databases from Liguria Region (Italy): the Nominative Cause of Death Registry, the Hospitalization Discharge Records and the Ligurian Resident Population Registry. As 10 subjects had moved out of town, information on vital status was obtained from their new local municipalities. The completeness of case findings from the sample was 498%. When an event was reported, original source documents were retrieved and reviewed to determine the occurrence of renal disease. All possible events were audited independently by two members of the endpoint committee. Events were coded according to the World Health Organization's International Classification of Diseases, Ninth Revision (ICD-9). Renal outcome was defined as the first hospitalization with a diagnosis of CKD (ICD-9 codes: 403.0, malignant hypertensive CKD; 403.1, benign hypertensive CKD; 403.9, unspecified hypertensive CKD; 404.0, malignant hypertensive heart and CKD; 404.1, benign hypertensive heart and CKD; 404.9, unspecified hypertensive heart and CKD; 585.1, stage I CKD; 585.2, stage II CKD; 585.3, stage III CKD; 585.4, stage IV CKD; 585.5, stage V CKD; 585.6, end-stage renal disease; 585.9, unspecified CKD; 586, unspecified renal failure; and 587, unspecified renal sclerosis). Survival time for the participant was defined as the period from the date of the baseline visit of the MAGIC study to the date of the first renal event or death or censoring date.
Statistical methods
Data are expressed as mean ± s.d., with the exception of skewed variables (that is, duration of hypertension, triglycerides and ACR), which are expressed as the median and interquartile range. Logarithmically transformed values of skewed variables were used for the statistical analysis. Comparisons between groups were made by analysis of variance. Comparisons of proportions among groups were made using the w 2 -test or Fisher's exact test when appropriate. Incidence rate of renal events was calculated. Kaplan-Meier and log-rank test methods were used to estimate and compare survival curves. Cox proportional hazard regression was used to estimate the hazard ratio (HR) and 95% confidence intervals (CIs) for the relationship between MS and MA to renal end point. Only first events were taken into consideration. Covariates that were considered as potential confounders of the relationship between MS and/or MA and renal outcome were included in the multivariate model. Model 1 was unadjusted, model 2 included gender and age and model 3 included age, gender, baseline glomerular filteration rate, uric acid level, systolic and diastolic BP, cigarette smoking and duration of hypertension.
Interactions between MA and MS on the risk of renal outcome were tested on both the multiplicative and additive scale. Multiplicative interaction was assessed by the use of the product term of the two variables in the Cox model. As described by Andersson et al., 17 additive interaction was measured by three indicators: (1) the relative excess risk due to interaction (RERI), (2) attributable proportion due to interaction (AP) and (3) synergy index (S). RERI is the excess risk caused by the interaction relative to the risk without exposure. AP refers to the attributable proportion of disease that is the result of the interaction among individuals with both exposures. S is the excess risk from exposure (to both exposures) when there is interaction relative to the risk from exposure (to both exposures) without interaction. RERI40, AP40 and S41 indicate causal interaction.
To explore the inter-relationship between MA and MS, we classified the study subjects into three groups: group 1, without MA or MS; group 2, with MA or MS; group 3, with MA and MS. Hazard ratios for groups 2 and 3 were determined relative to the hazard ratios of group 1.
Statistical analyses were performed using StatView for Windows (version 5.0.1; SAS Institute, Cary, NC, USA). Values of Po0.05 were considered statistically significant.
Results
Baseline characteristics of the 790 patients stratified according to MS status are shown in Table 1 . Overall, MS, as defined by the presence of two or more diagnostic criteria besides hypertension, was present in 19% (n ¼ 146) of patients. As expected, all the anthropometric and metabolic variables that were used to define MS were significantly different between the two groups, except BP. Furthermore, total cholesterol, LDL-cholesterol, serum uric acid and urinary albumin excretion were positively associated with MS.
During a median follow-up of 11.6 years (interquartile range 3.2 years), we observed a total of 8517 person-years for renal outcome. Overall, 80 renal events occurred, resulting in a cumulative incidence of 10%. The incidence rate of renal events was higher in subjects with MS (15.1 events per 1000 person-years) than in patients without MS at baseline (8.2 events per 1000 person-years; log-rank w 2 7.126; P ¼ 0.0076). Taking patients without MS as a reference, patients with MS had a 91% higher risk of reaching renal outcome (HR 1.91, 95% CI 1.18-3.10, P ¼ 0.0087). Furthermore, age-and sex-adjusted and fully adjusted HR (95% CI) was 1.99 (1.22-3.23) and 2.25 (1.24-4.08), respectively.
Of note, the prevalence of MA at baseline was significantly higher in subjects with MS (13.7 vs 6.2%; P ¼ 0.002). Cox regression analysis showed that the presence of MA is an independent predictor of renal outcome (unadjusted HR 2.71, 95% CI 1.56-4.69, P ¼ 0.0004; age-and gender-adjusted HR 2.30, 95% CI 1.29-4.08, P ¼ 0.0045; multivariate-adjusted HR 2.82, 95% CI 1.43-5.57, P ¼ 0.0028). Therefore, further analyses were performed to assess the potential additive role of MS and MA on renal events. When both MS and MA were included in the model, each one was independently associated with an increased risk of renal outcome, with a HR of 1.80 (95% CI 1.11-2.93, P ¼ 0.0182) for MS and 2.66 (95% CI 1.46-4.83, P ¼ 0.0014) for MA, respectively. The multiplicative interaction term of MS and MA was not significant when added to the above model (P ¼ 0.6019).
When patients were cross-stratified according to the presence of both MS and MA, the incidence of renal events increased progressively from patients with neither MS nor MA to those with only one of these abnormalities, and even further when both conditions were present at baseline (Figure 1 ). When MS and MA coexisted (n ¼ 20, 2.5%), the HR for renal outcome quintupled, as compared with what it was in patients with neither of these abnormalities (HR 5.47, 95% CI 3.80-7.90, Po0.0001). Additive interaction between MS and MA for renal outcome was present, as indicated by RERI (2.45, 95% CI 0.77-4.13), AP (0.45, 95% CI 0.17-0.73) and S (2.21, 95% CI 1.01-4.86).
We performed further analyses after reclassifying patients into three groups on the basis of the presence/absence of MS and MA, as reported in Table 2 . Diastolic and mean BP levels, serum uric acid, urinary albumin excretion and BMI were significantly higher, and lipid profile was worse in patients with one or both of these abnormalities compared with patients without MS or MA. Patients with both abnormalities had higher uric acid levels and urinary albumin excretion compared with patients with only one of the two abnormalities. Figure 2 shows the Kaplan-Meier survival curve according to the presence/absence of MS or MA. Survival analysis revealed that patients with both MS and MA at baseline had a more than fivefold greater risk of renal events, as compared with patients with neither of these risk factors, and the risk became even higher when potential confounders were taken into consideration (Table 3) .
Discussion
This study demonstrates that MS is a predictor of renal outcome in a cohort of non-diabetic patients with primary hypertension. Furthermore, the presence of MA increases the risk of renal events associated with MS. Regardless of MS, hypertensive patients are more likely to develop a renal event in the presence of MA. Of note, adjustment for conventional risk factors did not attenuate, but rather reinforced, this relationship.
The renal predictive role of MS was reported for the first time in over 10 000 non-diabetic American subjects who were included in the Atherosclerosis Risk in Communities study. 18 Over a 9-year followup period, the study showed that subjects with MS had a 43% multivariate-adjusted higher risk of developing CKD. More recently, similar results have been reported in general population cohorts from Southeast Asia 19, 20 and in patients with diabetes. 21 Our study extends the relationship between MS and the onset of CKD to non-diabetic patients with primary hypertension. Our findings, which show a twofold greater risk of CKD in patients with MS, are consistent with the results of the above-cited reports.
To date, the potentially additive role of MS and MA on renal outcomes has not yet been investigated. Increased urinary albumin excretion has often been reported in association with components of MS. 22, 23 However, considering the inconsistent relationship between MA and insulin resistance, 11, 12 suggesting, at least in part, different pathogenetic mechanisms, the information conveyed by the presence of MA might be complementary and possibly additive to the information regarding MS. We found a strong association between MA and MS; 1 in 7 patients among those with MS showed MA, whereas this figure decreased to 1 in 17 among patients without MS. Furthermore, our results showed that MA entails an increased risk of reaching renal end point to a similar extent as MS and also regardless of it. We also provide evidence of significant interaction between MS and MA, with regard to the risk of renal events. The joint effect of the two variables turned out to be larger than we expected from the sum of their individual effects. A synergy index of 2.21 indicates that there was a 121% relative excess risk compared with what would have been expected under an additive model, and the proportion of renal outcome attributable to the interaction of MS and MA was as high as 45%. On the other hand, the multiplicative interaction was not significant. Nonetheless, it must be pointed out that biological interactions can be better explained by additive rather than by multiplicative mechanisms. 24, 25 Furthermore, despite the reproducibility in different types of analyses, these results should be interpreted with some caution, given the relatively low number of patients showing MS and MA simultaneously.
The prevalence of MS and CKD in the general population is high and is rising at an alarming rate, especially in Western countries. Thus, acquiring better knowledge of the relationship among MA, MS and renal outcome may carry a clinical and socioeconomic relevance. This study does not allow us to draw conclusions regarding the pathophysiological mechanisms underlying the reported association; nonetheless, our data do lead us to make some considerations. Interestingly, the predictive power of MS and MA was independent of baseline glomerular filteration rate, as well as of other traditional cardiovascular and renal risk factors, such as gender, BP levels, smoking and serum uric acid (Table 3) . Thus, it seems that other factors, either still unknown or unaccounted for in our study, likely have a role in the onset of CKD.
Endothelial dysfunction might be the link between MS, MA and renal damage. In fact, MA is commonly thought to reflect the presence of endothelial dysfunction within the kidney, specifically at the glomerular level. 6 On the other hand, many variables included in MS are associated with endothelial dysfunction. 26, 27 Furthermore, as expected, the risk of new-onset diabetes increased when MS was present at baseline (OR ¼ 3.05, 95% CI; 1.23-7.61, P ¼ 0.0166), possibly contributing to the risk of developing CKD.
We acknowledge several limitations of this study. First of all, the lack of data on waist circumference may be a source of concern. Baseline evaluation of the patients took place between 1993 and 1997, a time when BMI was the most widely used parameter for assessing obesity. However, although the two indices have similar pathophysiological significance, 28 waist circumference has been shown to be poorly reproducible unless measured by specially trained personnel. 29 Second, the ICD-9-CM diagnosis codes that we used to assess end point have proven to be highly specific for detecting chronic renal insufficiency, even though they might lack in sensitivity. 30 As a result, in this study, the prevalence of new-onset chronic renal insufficiency may have been underestimated. Lastly, we have no data that would allow us to address the impact of treatment and BP control on the measurement of baseline albuminuria, as well as on the relationship between MS, MA and renal outcome, especially when one considers that the renoprotective effect of specific classes of antihypertensive drugs may differ.
In conclusion, this is the first study that highlights the potentially additional value of evaluating albuminuria and MS to predict long-term renal risk in patients with primary hypertension. Thus, their use should be more widely and systematically implemented in the clinical work-up of hypertensive patients as well as in predictive risk equations. In particular, our findings emphasize the usefulness of a more widespread evaluation of albuminuria, even in the absence of diabetes. Future studies may help clarify the impact of appropriate preventive and therapeutic measures on the development and progression of renal damage in hypertensive patients with MS and/or MA. 
